Table 2.
Surveillance Recommendations Following Surgical Resection
| Pathology | AGA (2015) | Fukuoka (2017) | ACG (2018) | European (2018) |
|---|---|---|---|---|
| Invasive cancer or dysplasia | MRI biennially | – | – | – |
| No HGD or cancer | No MRI surveillance | – | – | – |
| Invasive cancer in IPMN or MCN | – | Pancreatic cancer surveillance | Pancreatic cancer surveillance (stop after 5 years for MCN) | Pancreatic cancer surveillance |
| HGD or non-intestinal type IPMN | – | Q6m | Q6m | Q6m × 2 years, then annual MRI |
| Other IPMN | – | Q6–12 m | Q24m; if IPMN in remnant pancreas, follow non-resected IPMN surveillance | Follow non-resected IPMN surveillance |
| Non-invasive MCN, serous cystadenoma | – | No MRI surveillance | No MRI surveillance | – |